science

List of investigational other psychiatric disorder drugs

List of investigational other psychiatric disorder drugs is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand List of investigational other psychiatric disorder drugs rather than just read about it. In short: This is a list of investigational other psychiatric disorder drugs, or drugs that are currently under development for clinical use for the treatment of other or unspecified psychiatric disorders but are not yet approved. Some examples of such conditions include adjustment disorders, behavioral disorders, behavioral addictions like gambling addiction, impulse–control disorders, other personality disorders, and somato…

Key takeaways

List of investigational other psychiatric disorder drugs belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect List of investigational other psychiatric disorder drugs to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of List of investigational other psychiatric disorder drugs from memory before moving on to harder problems.

Reference excerpt

This is a list of investigational other psychiatric disorder drugs, or drugs that are currently under development for clinical use for the treatment of other or unspecified psychiatric disorders but are not yet approved. Some examples of such conditions include adjustment disorders, behavioral disorders, behavioral addictions like gambling addiction, impulse–control disorders, other personality disorders, and somatoform disorders. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]". This list was last comprehensively updated in January 2026. It is likely to become outdated with time.

Under development

Phase 3 Lumateperone (Caplyta; ITI-007; ITI-722) – non-selective monoamine receptor modulator – behavioral disorders [1] Lurasidone (DSP-1349M; Latuda; SM-13496; SMP-13496) – atypical antipsychotic (non-selective monoamine receptor modulator) – psychiatric disorders [2] Ralmitaront (NTX-2001; RG-7906; RO-6889450) – trace amine-associated receptor 1 (TAAR1) agonist – psychiatric disorders [3] Venlafaxine extended-release (ALM-002; ALM002) – undefined mechanism of action – mental disorders [4] [5]

Phase 2/3 Evenamide (NW-3509; NW-3509A) – sodium channel blocker – psychiatric disorders [6] Psilocybin (CYB001; CYB-001; INT0052/2020) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, serotonergic psychedelic – mental disorders [7]

Phase 2 ALM-007 (ALM007) – undefined mechanism of action – psychiatric disorders [8] [9] Deudextromethorphan (AVP-786; CTP-786; d-DM; deuterated-DM; deuDXM; deu-DXM; deuterated DXM) – NMDA receptor antagonist, sigma receptor agonist, other actions – impulse–control disorders [10] Fasedienol (Aloradine; AM-005; PH-94B; PH94B) – vomeropherine (chemoreceptor cell modulator) – adjustment disorders [11] Psilocybin (COMP360; COMP-360) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, serotonergic psychedelic – somatoform disorders [12] Psilocybin (PEX-010) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, serotonergic psychedelic – adjustment disorders [13] SRX-246 (SRX246; API-246) – vasopressin V1A receptor antagonist – impulse–control disorders [14] SXC-2023 – cystine–glutamate antiporter (SLC7A11; System xc- or Sxc) activator – impulse–control disorders [15] [16]

Phase 1/2 SRX-246 (SRX246; API-246) – vasopressin V1A receptor antagonist – behavioral disorders [17]

Phase 1 5-MeO-MiPT (MSD-001; MS001; MSD-101; MSD-201; MSD-X01) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, serotonergic psychedelic – mental disorders [18] CVN-766 (CVN766) – orexin OX1 receptor antagonist – psychiatric disorders [19] "Glutamate receptor modulator" - Boehringer Ingelheim – glutamate receptor modulator – mental disorders [20] KNX-100 (KNX100; SOC-1) – oxytocin-like drug / indirect oxytocin receptor modulator – behavioral disorders [21] MSP-2020 (MSP2020) – serotonin 5-HT2A receptor agonist – mental disorders [22] [23] NBI-1140675 – vesicular monoamine transporter 2 (VMAT2) inhibitor – psychiatric disorders [24] Radiprodil (RGH-896) – ionotropic glutamate NR2B-containing NMDA receptor antagonist – behavioral disorders [25] "Receptor agonist" - Boehringer Ingelheim – undefined mechanism of action – mental disorders [26] SYT-510 (SYT510) – endocannabinoid reuptake inhibitor – psychiatric disorders [27]

Clinical phase unknown Eplivanserin/volinanserin – fixed-dose combination of eplivanserin (serotonin 5-HT2A receptor antagonist) and volinanserin (serotonin 5-HT2A receptor antagonist) – psychiatric disorders [28] [29]

Preclinical Aripiprazole controlled release (LYN-006; ultra long-acting aripiprazole) – atypical antipsychotic (non-selective monoamine receptor modulator) – psychiatric disorders [30] CYB-210010 (CYB210010; 2C-T-TFM; 2C-T-36) – serotonin 5-HT2 receptor agonist and serotonergic psychedelic – psychiatric disorders [31] Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α2-adrenergic receptor agonist – psychiatric disorders [32] DT-201 (DT201) – α5 subunit-containing GABAA receptor negative allosteric modulator – psychiatric disorders [33] KAR-501 (KAR501) – undefined mechanism of action – mental disorders [34] Lu AG06474 (Lu-AG-06474) – monoacylglycerol lipase (MAGL) inhibitor – psychiatric disorders [35] Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABAA receptor positive allosteric modulator) – gambling [36] NBI-1065890 (NBI-890) – vesicular monoamine transporter 2 (VMAT2) inhibitor – psychiatric disorders [37] ORX-489 (ORX489) – orexin OX2 receptor antagonist – psychiatric disorders [38] OV-350 (AZ-8333) – potassium–chloride-cotransporter agonist – psychiatric disorders [39] TPT-0301 (neuropathic pain therapeutic) – cannabinoid receptor modulator – mental disorders [40]

Research OWP-107 (OWP107) – undefined mechanism of action – psychiatric disorders [41] Psilocybin (REL-P11) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, serotonergic psychedelic – psychiatric disorders [42] Research programme: mental disorder therapies - Mindstate Design Labs (MSD-X02) – undefined mechanism of action – mental disorders [43]

Not under development

… excerpt ends here. Continue reading the full article.

Worked examples

Example 1 — a first encounter with List of investigational other psychiatric disorder drugs

Start with the simplest possible case. Write down what List of investigational other psychiatric disorder drugs claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to List of investigational other psychiatric disorder drugs before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about List of investigational other psychiatric disorder drugs ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of List of investigational other psychiatric disorder drugs

In research: List of investigational other psychiatric disorder drugs appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses List of investigational other psychiatric disorder drugs in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: List of investigational other psychiatric disorder drugs is common in secondary-school and first-year university syllabi. It links to neighbouring topics Experimental psychiatric drugs, Lists of investigational drugs, so understanding it makes those chapters shorter.
In everyday life: Look for List of investigational other psychiatric disorder drugs outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “List of investigational other psychiatric disorder drugs” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study List of investigational other psychiatric disorder drugs in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what List of investigational other psychiatric disorder drugs means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain List of investigational other psychiatric disorder drugs out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is List of investigational other psychiatric disorder drugs in simple terms?

Why does List of investigational other psychiatric disorder drugs matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study List of investigational other psychiatric disorder drugs?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on List of investigational other psychiatric disorder drugs.